Form 4: Moderna President Stephen Hoge Reports Stock Transactions

Stephen Hoge, President of Moderna, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

Summary

• Stephen Hoge, President of Moderna, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2025, Hoge acquired 652 and 611 shares of common stock through the conversion of restricted stock units.
• Also on February 28, 2025, Hoge disposed of 316 and 296 shares of common stock to satisfy tax withholding obligations at a price of $31.09 per share.
• Hoge also reports ownership of common stock held indirectly through Valhalla, LLC (4,116 shares) and a trust (151,933 shares).
• On March 1, 2025, Hoge was granted a stock option to buy 238,043 shares and 148,524 restricted stock units.
• The reported transactions leave Hoge with direct ownership of 1,450,727 shares of common stock, 2,607 and 4,884 restricted stock units, and a stock option for 238,043 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of stock transactions, with no inherently positive or negative implications for the company's outlook.

Positives

• The granting of stock options and restricted stock units to a key executive like the President can be seen as an incentive to drive company performance.
• The vesting schedules for the new options and restricted stock units are spread out over time, aligning the executive's interests with the long-term success of the company.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's direct stake in the company.

Risks

• Significant stock transactions by executives can sometimes be interpreted negatively by the market if not clearly explained, although in this case, the tax-related sales are routine.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest a long-term commitment from the executive.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biotech industry where equity compensation is a significant part of executive pay. These transactions are closely watched by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotechnology industry, similar to companies like Pfizer, BioNTech, and Novavax.
• Vesting schedules, such as the quarterly installments described, are also typical to ensure long-term alignment with company performance, mirroring practices seen at Regeneron and Gilead Sciences.
• Tax-related stock sales are a routine part of equity compensation and are not unique to Moderna or its executives.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into executive sentiment.
• Employees may view these transactions as part of the overall compensation structure.

Key Dates